Back to mobile site
Get it on Google Play

Bayer's KERENDIA gets FDA priority review for type 1 diabetes treatment

May 21, 2026 2:30 AM EDT Send to a Friend
Bayer announced that the U.S. Food and Drug Administration accepted its supplemental New Drug Application and granted priority review designation ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login